40.45Open40.45Pre Close0 Volume7 Open Interest200.00Strike Price0.00Turnover51.54%IV-4.96%PremiumDec 20, 2024Expiry Date53.01Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9841Delta0.0014Gamma4.72Leverage Ratio-0.0541Theta0.0948Rho4.64Eff Leverage0.0222Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet